Access icon

This article is freely available to all

Article Abstract

Sir: Risperidone, a recently introduced novel antipsychotic, is associated with a low incidence of seizures. During premarketing testing, seizures occurred in 0.3% (9/2607) of risperidone-treated patients (with dosages unrevealed), two in association with hyponatremia. To our knowledge, no postmarketing risperidone-associated seizure has been reported. We describe an elderly schizophrenic woman who developed a single seizure after 2 days of coadministration of risperidone, sulfamethoxazole-trimethoprim, and astemizole.